Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23616081 | 0.78 | KCNN4 (0.43) | KCNN4CES2CES1CHRM3TRPA1 | |
| SCHEMBL2147584 | 0.74 | PDE2A (0.50) | KCNN4CES2TRPA1PDE2A | |
| SCHEMBL29827588 | 0.74 | PDE2A (0.50) | KCNN4CES2TRPA1PDE2A | |
| SCHEMBL23219438 | 0.73 | RIPK1 (0.36) | KCNN4CHRM3TRPA1HDAC3HDAC1 | |
| Lithium SCHEMBL2459422 | 0.72 | PDE2A (0.48) | KCNN4CES2TRPA1PDE2A | |
| SCHEMBL4473460 | 0.72 | KCNN4 (0.41) | KCNN4CES2CES1CHRM3TRPA1 | |
| SCHEMBL2459420 | 0.72 | PDE2A (0.48) | KCNN4CES2TRPA1PDE2A | |
| SCHEMBL9576388 | 0.72 | TSHR (0.48) | KCNN4CES2CES1CHRM3TRPA1 | |
| SCHEMBL3950869 | 0.72 | ESR1 (0.44) | KCNN4CES2CES1CHRM3HDAC3 | |
| SCHEMBL828570 | 0.72 | ALDH1A1 (0.46) | KCNN4CES2CES1CHRM3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845538-B1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20210386737-A1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2021-12-16 | — | — | US | disclosed |
| EP-3845538-A1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2021-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386737-A1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | BRAF, NRAS, RAF1 | KCNN4 3461/4885CES2 4761/4885CES1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.